WAVE Life Sciences Ltd
WVE
查看详细走势图
6.615USD
+0.415+6.69%
收盘 03/30, 16:00（美东）报价延迟15分钟
138.47M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+6.69%
5天
-43.75%
1月
-52.51%
6月
-7.22%
今年开始到现在
-61.09%
1年
-23.26%
查看详细走势图
TradingKey WAVE Life Sciences Ltd股票评分
单位: USD 更新时间: 2026-03-27操作建议
WAVE Life Sciences Ltd当前公司基本面数据相对非常健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名85/391位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价35.12。中期看，股价处于下降通道。近一个月，市场表现非常差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
WAVE Life Sciences Ltd评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
WAVE Life Sciences Ltd亮点
亮点风险
Wave Life Sciences Ltd. is a biotechnology company focused on unlocking the broad potential of ribonucleic acid (RNA) medicines to transform human health. The Company’s RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. The Company’s diversified pipeline includes clinical programs in alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington’s disease, as well as several preclinical programs utilizing the Company’s broad RNA therapeutics toolkit. Its programs include WVE-006, SERPINA1 (AATD); WVE-007 (GalNAc), INHBE (Obesity); WVE-N531, Exon 53 (DMD), and WVE-003, mHTT (HD).
业绩增长期
公司处于发展阶段，最新年度总收入42.73M美元
利润高增长
公司净利润处于行业前列，最新年度总收入42.73M美元
估值高估
公司最新PE估值-5.25，处于3年历史高位
景顺投资公司持仓
明星投资者景顺投资公司持仓，最新持仓市值125.77K
分析师目标
根据
16
位分析师
买入
评级
28.313
目标均价
+356.65%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
WAVE Life Sciences Ltd新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
WAVE Life Sciences Ltd简介
Wave Life Sciences Ltd. is a biotechnology company focused on unlocking the broad potential of ribonucleic acid (RNA) medicines to transform human health. The Company’s RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. The Company’s diversified pipeline includes clinical programs in alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington’s disease, as well as several preclinical programs utilizing the Company’s broad RNA therapeutics toolkit. Its programs include WVE-006, SERPINA1 (AATD); WVE-007 (GalNAc), INHBE (Obesity); WVE-N531, Exon 53 (DMD), and WVE-003, mHTT (HD).
公司代码WVE
公司WAVE Life Sciences Ltd
CEOBolno (Paul B)
网址https://www.wavelifesciences.com/
相关品种
